Corrigendum to: Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus (Human Vaccines & Immunotherapeutics, 11, 02, (504–515), 10.4161/21645515.2014.987006);Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 gag and Env proteins expressed by newcastle disease virus

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 2, 2015, Pages 504-515

  Khattar, Sunil K ^a   Palaniyandi, Senthilkumar ^a   Samal, Sweety ^a   Labranche, Celia C ^b   Montefiori, David C ^b   Zhu, Xiaoping ^a   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Guinea pigs; HIV 1 Env; HIV 1 Gag; Immune responses; Mice; Newcastle disease virus

Indexed keywords

APRAXIA; ARTICLE; GESTURE; HUMAN; LANGUAGE; LEARNING; MOTOR PERFORMANCE; PHONETICS; RHYTHM; SOMATOSENSORY SYSTEM; SPEECH; VOCAL CORD; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; GENETICS; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; MUCOSAL IMMUNITY; NEWCASTLE DISEASE VIRUS; SECRETION (PROCESS);

DRUG CARRIER; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, ENV; GUINEA PIGS; HIV ANTIBODIES; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INTERFERON-GAMMA; MICE; NEWCASTLE DISEASE VIRUS; VACCINES, SYNTHETIC;

EID: 84929091266     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1172884     Document Type: Erratum

References (46)

1. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10; PMID:10655111
2. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-4; http://dx.doi.org/10.1038/nature10660
3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-6; PMID:10655110
4. Excler JL, Robb ML, Kim JH. HIV-1 vaccines: Challenges and new perspectives. Hum Vaccin Immunother 2014; 10; PMID:24637946; http://dx.doi.org/10.4161/hv.28462
5. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce? Science 2014; 345:167-8; PMID:25013066; http://dx.doi.org/10.1126/science.1256526
6. Su B, Moog C. Which Antibody Functions are Important for an HIV Vaccine? Front Immunol 2014; 5:289; PMID:24995008; http://dx.doi.org/10.3389/fimmu. 2014.00289
7. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93; PMID:22217938; http://dx.doi.org/10.1038/nature10766
8. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8C cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10; PMID:8057491
9. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4CT cell responses associated with control of viremia. Science 1997; 278:1447-50; PMID:9367954
10. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5; PMID:8207839
11. McDermott AB, Koup RA. CD8(C) T cells in preventing HIV infection and disease. Aids 2012; 26:1281-92; PMID:22441256
12. Blackbourn DJ, Mackewicz CE, Barker E, Hunt TK, Herndier B, Haase AT, Levy JA. Suppression of HIV replication by lymphoid tissue CD8C cells correlates with the clinical state of HIV-infected individuals. Proc Natl Acad Sci U S A 1996; 93:13125-30; PMID:8917555
13. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173-8; PMID:16369537
14. Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8C T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011; 6:169-73; PMID:21399496; http://dx.doi.org/10.1097/COH.0b013e3283454c39
15. Greene JM, Lhost JJ, Burwitz BJ, Budde ML, Macnair CE, Weiker MK, Gostick E, Friedrich TC, Broman KW, Price DA, et al. Extralymphoid CD8C T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo. J Virol 2010; 84:3362-72; PMID:20089651; http://dx.doi.org/10.1128/JVI.02028-09.
16. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-7; PMID:21562493; http://dx.doi.org/10.1038/nature10003
17. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, et al. Control of viremia in simian immunodeficiency virus infection by CD8C lymphocytes. Science 1999; 283:857-60; PMID:9933172
18. Hansen SG, Piatak M, Jr., Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100-4; PMID:24025770; http://dx.doi.org/10.1038/nature 12519
19. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8C T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305; PMID:11836408
20. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung’u T, Walker BD. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 2010; 84:5540-9; PMID:20335261; http://dx.doi.org/10.1128/JVI.02031-09
21. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8C T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53; PMID:17173051
22. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, Takeda A, Moriya C, Takeuchi H, Akari H, Matano T. Gag-specific cytotoxic T-lymphocytebased control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 2008; 82:10199-206; PMID:18667518; http://dx.doi.org/10.1128/JVI.01103-08
23. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91; PMID:18997770; http://dx.doi.org/10.1038/nature07469
24. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 2005; 79:13275-84; PMID:16227250
25. Nakaya Y, Nakaya T, Park MS, Cros J, Imanishi J, Palese P, Garcia-Sastre A. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol 2004; 78:9366-75; PMID:15308731
26. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, Cros J, Mertz SE, Jewell NA, Hammond S, Flano E, Durbin RK, Garcia-Sastre A, et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 2006; 80:1130-9; PMID:16414990
27. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 2007; 104:9788-93; PMID:17535926
28. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virusvectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010; 29: 17-25; PMID:21034822
29. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, et al. Newcastle disease virusvectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010; 84:1489-503; PMID:19923177; http://dx.doi.org/10.1128/JVI.01946-09
30. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P. Recombinant Newcastle disease virus as a vaccine vector. J Virol 2001; 75:11868-73; PMID:11689668
31. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 2011; 85:10529-41; PMID:21849467
32. Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL, Samal SK. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PloS one 2013; 8:e78521; PMID:24098600
33. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12:509-17; PMID:21739679
34. Xu R, Nasar F, Megati S, Luckay A, Lee M, Udem SA, Eldridge JH, Egan MA, Emini E, Clarke DK. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques. J Virol 2009; 83:9813-23; PMID:19625392
35. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1989; 86:5781-5; PMID:2788277
36. Toapanta FR, Craigo JK, Montelaro RC, Ross TM. Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res 2007; 5:199-209; PMID:17346134
37. Hovav AH, Santosuosso M, Bivas-Benita M, Plair A, Cheng A, Elnekave M, Righi E, Chen T, Kashiwagi S, Panas MW, et al. X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens. J Virol 2009; 83:10941-50; PMID:19692474
38. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, Fauci AS. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{a} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2007; 104:3396-401; PMID:17360657
39. Lopez D, Samino Y, Koszinowski UH, Del Val M. HIV envelope protein inhibits MHC class I presentation of a cytomegalovirus protective epitope. J Immunol 2001; 167:4238-44
40. Bockl K, Wild J, Bredl S, Kindsmuller K, Kostler J, Wagner R. Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine. PloS one 2012; 7:e34723; PMID:22509350
41. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993; 67:4822-30; PMID:8392616
42. Huang Z, Krishnamurthy S, Panda A, Samal SK. Highlevel expression of a foreign gene from the most 3’-proximal locus of a recombinant Newcastle disease virus. J Gen Virol 2001; 82:1729-36; PMID:11413385
43. Huang Z, Krishnamurthy S, Panda A, Samal SK. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an a interferon antagonist. J Virol 2003; 77:8676-85; PMID:12885886
44. Krishnamurthy S, Huang Z, Samal SK. Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 2000; 278: 168-82; PMID:11112492
45. Alexander DJ. Newcastle disease and other avian Paramyxoviridae infection Ames, IA: Iowa State University Press, 1997
46. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25; PMID:16051804